HUTCHMED H2 Earnings Call Highlights [Yahoo! Finance]
HUTCHMED (China) Limited - American Depositary Shares (HCM)
NASDAQ:AMEX Investor Relations:
chi-med.com/investors/information-for-shareholders
Company Research
Source: Yahoo! Finance
than 38 countries, while China sales rebounded in H2 (up 21% vs H1) driven mainly by endometrial cancer reimbursement expansion. The company reported consolidated profit of $457 million, largely from a $416 million gain on a partial SPL equity divestment, with oncology revenue of $286 million (including $71 million in R&D-related upfronts) and about $1.4 billion in cash; 2026 oncology revenue guidance is $330–$450 million. R&D strategy is shifting toward an expanding ATTC platform—R&D spend fell to $148 million in 2025 but may rise toward an indicative $200–$300 million as ATTC programs (251, 580 and 830) enter and progress through global clinical development. Interested in HUTCHMED (China) Limited Sponsored ADR? Here are five stocks we like better. HUTCHMED (NASDAQ:HCM) management used its 2025 annual results call to highlight growth in global sales for FRUZAQLA, a rebound in China market performance in the second half, and increasing investment behind its ATTC (antibody-targ
Show less
Read more
Impact Snapshot
Event Time:
HCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HCM alerts
High impacting HUTCHMED (China) Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
HCM
News
- HUTCHMED Reports 2025 Full Year Results and Business UpdatesGlobeNewswire
- HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid TumorsGlobeNewswire
- HUTCHMED to Announce 2025 Final ResultsGlobeNewswire
- HUTCHMED (NASDAQ:HCM) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.MarketBeat
- HUTCHMED Highlights Publication of Phase III SACHI Results in The LancetGlobeNewswire
HCM
Sec Filings
- 3/5/26 - Form 6-K
- 3/5/26 - Form 20-F
- 3/4/26 - Form 6-K
- HCM's page on the SEC website